|
Market Closed -
Nasdaq
00:00:00 04/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 23.66 USD | -0.80% |
|
-4.87% | -18.53% |
| 08-25 | Oruka Therapeutics Names Chief Commercial Officer | MT |
| 08-20 | Arcutis Biotherapeutics' Zoryve Gets Health Canada Approval for Children With Atopic Dermatitis | MT |
| Market Cap | 2.97B 2.56B 2.4B 2.2B 4.1B 281B 4.13B 28.4B 11.06B 144B 11.17B 10.92B 463B | P/E 2026 * |
60.9x | P/E 2027 * | 18.9x |
|---|---|---|---|---|---|
| Enterprise Value | 2.69B 2.31B 2.17B 1.98B 3.7B 254B 3.73B 25.65B 9.99B 130B 10.08B 9.86B 418B | EV / Sales 2026 * |
5x | EV / Sales 2027 * | 3.41x |
| Free-Float |
98.22% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ARQT | Delayed | |
CBOE
| ARQT | Real-time |
Last Transcript : Arcutis Biotherapeutics, Inc.
| 1 day | -0.80% | ||
| 1 week | -4.87% | ||
| Current month | -1.29% | ||
| 1 month | -8.79% | ||
| 3 months | +10.82% | ||
| 6 months | +0.25% | ||
| Current year | -18.53% |
| 1 week | 23.21 |  | 24.45 |
| 1 month | 23.21 | | 29.24 |
| Current year | 19.3 | | 30.75 |
| 1 year | 16.21 | | 31.77 |
| 3 years | 1.76 | | 31.77 |
| 5 years | 1.76 | | 31.77 |
| 10 years | 1.76 | | 40.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Todd Watanabe
CEO | Chief Executive Officer | 58 | 01/04/2017 |
| Corporate Officer/Principal | 71 | 03/12/2025 | |
Latha Vairavan
DFI | Director of Finance/CFO | - | 15/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Patrick Heron
CHM | Chairman | 55 | 01/12/2019 |
Todd Watanabe
BRD | Director/Board Member | 58 | 01/01/2016 |
Howard Welgus
BRD | Director/Board Member | 74 | 01/08/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 27/08/26 | Exercice | Director | 114,600 | 0.0916% | ||
| 20/08/26 | Exercice | Director | 3,216 | 0.0026% | ||
| 19/08/26 | Sell | Chief Technology Officer | -1,697 | 0.0014% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.80% | -4.87% | +48.43% | +164.06% | 3B | |
| -1.00% | +4.43% | +49.60% | +1.42% | 85.08B | |
| -1.29% | +4.27% | +519.00% | +32.26% | 60.21B | |
| -0.21% | +1.60% | -16.97% | -34.78% | 59.71B | |
| -1.60% | -7.34% | -5.08% | +31.05% | 51.1B | |
| +0.09% | -0.54% | +9.26% | +165.71% | 48.73B | |
| +0.83% | +1.36% | +58.53% | -15.97% | 32.9B | |
| -0.64% | +0.20% | +47.19% | +97.87% | 26.11B | |
| -0.10% | -4.65% | +2.40% | +197.10% | 22.6B | |
| +1.10% | -1.67% | +64.17% | +118.01% | 16.42B | |
| Average | -0.37% | -0.72% | +77.65% | +75.67% | 40.59B | |
| Weighted average by Cap. | -0.57% | +0.67% | +96.23% | +45.74% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 537M 462M 434M 397M 740M 50.76B 746M 5.13B 2B 25.94B 2.02B 1.97B 83.54B | 686M 590M 553M 506M 945M 64.8B 953M 6.55B 2.55B 33.12B 2.57B 2.52B 107B |
| Net income | 51.79M 44.56M 41.82M 38.26M 71.41M 4.9B 71.97M 495M 193M 2.5B 194M 190M 8.06B | 168M 144M 136M 124M 231M 15.87B 233M 1.6B 625M 8.11B 631M 617M 26.12B |
| Net Debt | -288M -248M -233M -213M -398M -27.26B -401M -2.75B -1.07B -13.93B -1.08B -1.06B -44.87B | -638M -549M -515M -471M -879M -60.29B -886M -6.09B -2.37B -30.81B -2.39B -2.34B -99.23B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/09/26 | $23.66 | -0.80% | 1,122,316 |
| 02/09/26 | $23.85 | +0.42% | 1,950,718 |
| 01/09/26 | $23.75 | -0.92% | 1,101,734 |
| 31/08/26 | $23.97 | +0.80% | 1,522,731 |
| 28/08/26 | $23.78 | -4.38% | 1,536,018 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ARQT Stock
Select your edition
All financial news and data tailored to specific country editions
